No Data
No Data
Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
The market rallied behind Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) stock, leading do a rise in the share price after its recent weak earnings report. We think that shareholders might be
Harbin Pharmaceutical Co., Ltd. (600664.SH): Net profit of 177 million yuan in the first quarter increased by 44.52% year-on-year
On April 25, Ge Longhui Co., Ltd. (600664.SH) released its first quarter report. Operating revenue was 4.142 billion yuan, up 5.36% year on year, net profit of 177 million yuan, up 44.52% year on year, after deducting non-net profit of 159 million yuan, up 43.11% year on year, with basic earnings of 0.07 yuan per share.
Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan
Harbin Pharmaceutical Group (SHA:600664) plans to upgrade the digital system of subsidiary Sanjing Pharmaceutical's oral liquid production base for 49.7 million yuan, the company said in its filing on
Harbin Pharmaceutical Co., Ltd. (600664.SH) plans to donate medicines and medical devices worth no more than 37 million yuan to public welfare organizations
Harbin Pharmaceutical Co., Ltd. (600664.SH) issued an announcement. The company held the 2nd meeting of the 10th board of directors on April 10, 2024 to review and pass the “Proposal on Foreign Donations”, agreeing that the company will donate drugs and medical equipment worth no more than 37 million yuan to public welfare organizations to carry out public welfare activities such as poverty alleviation, rural revitalization, one old, one small, and sudden disasters.
Harbin Pharmaceutical Co., Ltd. (600664.SH) plans to build a digital upgrade project for Sanjing Pharmaceutical Oral Liquids Workshop 1
Harbin Pharmaceutical Co., Ltd. (600664.SH) announced that Sanjing Pharmaceutical, a wholly-owned subsidiary of the company, is the company's oral liquid production base. The base is located at No. 233, Haping Road, Xiangfang District, Harbin. According to the company's plan, it is proposed to adjust the process layout of the sterilization and packaging process of Sanjing Pharmaceutical's oral liquid workshop, introduce an automatic sterilization system and packing and palletizing system; complete the construction of a SCADA system and build a factory-level MES platform; and reserve a port for subsequent vehicle intake while the digital system is put into use. The total investment of this project is 49.7 million yuan. The project capital comes from Sanjing Pharmaceutical's own capital.
Harbin Pharmaceutical Co., Ltd. (600664.SH) issued 2023 results, with net profit of 395 million yuan, a year-on-year decrease of 15.02%
Harbin Pharmaceutical Co., Ltd. (600664.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 15.457 billion yuan, an increase of 11.93%; net profit attributable to shareholders of listed companies was 395 million yuan, a year-on-year decrease of 15.02%; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 325 million yuan, an increase of 40.50% year-on-year; and basic earnings per share were 0.16 yuan/share.
No Data